Research Team Completes Clinical Trial of Herbal Immunomodulator Candidates for COVID-19 Patients

The research, which was started on June 8, involved 90 study subjects aged 18-50 years who were given intervention for 14 days. The criteria for the study subjects were new positive COVID-19 patients who had been confirmed through Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and had mild pneumonia symptoms. The subject is not pregnant or suffering from other diseases such as dengue fever, typhoid fever, heart problems, kidney problems, or allergies to the products tested.

The research used a randomized and double blind blinding system so that the subject and the researcher did not know whether what was given to the subject was one of the products tested or a placebo.

“The clinical trial method of immunomudolator candidates was carried out in double-blind randomized controlled trials with placebo to avoid bias in the study,” explained Masteria, citing a release received by Health-Liputan6.com.

There were two test products and one placebo that were given randomly and evenly on 90 test subjects who were divided into three groups. The first group received standard therapy for COVID-19 and IP1, group two received standard therapy for COVID-19 and IP2, and the control group received standard therapy for COVID-19 and placebo.

The main aim of clinical trials is to see if the time needed to achieve improvement in non-specific clinical symptoms is shorter in duration.

“Clinical trials are also aimed at finding out how long it will take to achieve a negative RT-PCR result after improvement in clinical symptoms,” said Masteria.

–